Abstract
Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, p = 0.033; OS, not available vs. 28.2 months, p = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion (p < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion.
Highlights
IntroductionAccording to the World Health Organization classification, Biliary tract carcinoma (BTC) includes perihilar and distal extrahepatic bile duct carcinoma and gallbladder carcinoma [2]
Biliary tract carcinoma (BTC) is a relatively rare cancer worldwide [1]
This study investigated the postoperative outcomes of BTC resection with the administration of S-1 as adjuvant chemotherapy
Summary
According to the World Health Organization classification, BTC includes perihilar and distal extrahepatic bile duct carcinoma and gallbladder carcinoma [2]. Major hepatectomy with extra bile duct resection is performed for perihilar carcinoma, and pancreaticoduodenectomy is the most common approach for distal cholangiocarcinoma. The benefit of adjuvant chemotherapy after the surgical treatment of several advanced cancers, such as gastric cancer [4,5,6], colon cancer [7,8], and pancreatic cancer [9], is well established. Various adjuvant chemotherapy regimens are reported to improve the prognosis of patients with such cancers. In the case of BTC, the few large randomized trials on adjuvant chemotherapy conducted to date have produced unpromising results [10,11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
